Program
Liraglutide
Also written as “liraglutide”, “insulin degludec/liraglutide” and “Insulin degludec/liraglutide”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Diabetes Mellitus, Type 1 · Osteoarthritis, Knee, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 972 open or running | phase 4since Jul 22, 2013 | Sep 8, 2005 | Dec 13, 2026phase 1 · NCT07225816 |
| 4Moving Biotech | 20 open or running | phase 2since Sep 24, 2025 | Jun 7, 2022 | none ahead |
| Eli Lilly | 20 open or running | phase 4since Feb 24, 2014 | May 31, 2013 | none ahead |
| Tonghua Dongbao Pharmaceutical | 22 open or running | phase 3since Aug 14, 2024 | Jun 2, 2024 | none ahead |
| Biolingus | 11 open or running | phase 2since Feb 16, 2022 | Feb 16, 2022 | none ahead |
| Cinnagen | 10 open or running | phase 3since Jan 29, 2018 | Jan 29, 2018 | none ahead |
| ikfe-cro-gmbh | 10 open or running | phase 4since Sep 17, 2010 | Sep 17, 2010 | none ahead |
| Merck | 10 open or running | phase 1since Jun 13, 2011 | Jun 13, 2011 | none ahead |
| Pfizer | 10 open or running | phase 1since Feb 1, 2017 | Feb 1, 2017 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 1since Aug 24, 2021 | Aug 24, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 42 studies since Jan 16, 2012.
- Sep 20, 20162 phase 3 studiesNovo Nordisk · NCT02911948, NCT02918279
- Nov 10, 20163 phase 3 studiesNovo Nordisk · NCT02963935, NCT02963922, NCT02964247
- Feb 1, 2017Pfizer's first study: phase 1 study in ObesityNew to PfizerPfizer · NCT03041792 · 61 enrolled · United States
- May 24, 20172 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT03175120, NCT03172494
- Sep 19, 2017Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03292185 · 24 enrolled · China
- Jan 29, 2018Cinnagen's first study: phase 3 study in Diabetes Mellitus, Type 2New to CinnagenCinnagen · NCT03421119 · 300 enrolled
- Feb 26, 2021Phase 3 study in ObesityNovo Nordisk · NCT04775082 · 82 enrolled · United States, Belgium, India and more
- Aug 24, 2021Sino Biopharmaceutical's first study: phase 1 study in Diabetes Mellitus, Type 2New to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05029076 · 28 enrolled · China
- Feb 16, 2022Biolingus's first study: phase 2 study in Diabetes Mellitus, Type 2New to BiolingusBiolingus · NCT05268237 · 15 planned · Hong Kong
- Jun 7, 20224Moving Biotech's first study: phase 1 study in Osteoarthritis, KneeNew to 4Moving Biotech4Moving Biotech · NCT05419856 · 34 enrolled · Belgium
- Jun 2, 2024Tonghua Dongbao Pharmaceutical's first study: phase 1 study in HealthyNew to Tonghua Dongbao PharmaceuticalTonghua Dongbao Pharmaceutical · NCT06449703 · 44 planned · China
- Aug 14, 2024Phase 3 study in Diabetes Mellitus, Type 2Tonghua Dongbao Pharmaceutical · NCT06559722 · 510 planned
- Sep 24, 2025Phase 2 study in Osteoarthritis, Knee4Moving Biotech · NCT07225829 · 130 enrolled · United States, Canada, Denmark and more
- Nov 5, 2025Phase 1 study in ObesityNovo Nordisk · NCT07225816 · 71 planned · United States
Ahead
- Dec 13, 2026Primary completion: phase 1 study in ObesityNovo Nordisk · NCT07225816
TargetBeta
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
| efpeglenatiderule | Hanmi Pharmaceutical | phase 3 | 13 |
Studies
The newest 60 of 109 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07225816Obesity · United States | 1 | Recruiting | Novo Nordisk | Dec 13, 2026 | 71 |
| NCT07225829Osteoarthritis, Knee · United States, Canada, Denmark and more | 2 | Completed | 4Moving Biotech | Aug 31, 2026 | 130 |
| NCT06559722Diabetes Mellitus, Type 2 | 3 | Not yet recruiting | Tonghua Dongbao Pharmaceutical | Oct 2025 | 510 |
| NCT06449703Healthy · China | 1 | Recruiting | Tonghua Dongbao Pharmaceutical | Jun 16, 2024 | 44 |
| NCT05419856Osteoarthritis, Knee · Belgium | 1 | Completed | 4Moving Biotech | Oct 31, 2023 | 34 |
| NCT05268237Diabetes Mellitus, Type 2 · Hong Kong | 2 | Recruiting | Biolingus | Dec 2025 | 15 |
| NCT05029076Diabetes Mellitus, Type 2 · China | 1 | Completed | Sino Biopharmaceutical | Jun 1, 2019 | 28 |
| NCT04775082Obesity · United States, Belgium, India and more | 3 | Active, not recruiting | Novo Nordisk | Aug 1, 2023 | 82 |
| NCT03421119Diabetes Mellitus, Type 2 | 3 | UNKNOWN | Cinnagen | Dec 1, 2019 | 300 |
| NCT03292185Diabetes Mellitus · China | 1 | Completed | Novo Nordisk | Jan 2, 2018 | 24 |
| NCT03175120Diabetes Mellitus · China, Hong Kong | 3 | Completed | Novo Nordisk | Mar 5, 2019 | 453 |
| NCT03172494Diabetes Mellitus · China | 3 | Completed | Novo Nordisk | Jun 14, 2019 | 720 |
| NCT03041792Obesity · United States | 1 | Completed | Pfizer | Jan 16, 2018 | 61 |
| NCT02964247Diabetes Mellitus · United States, Brazil, India and more | 3 | Completed | Novo Nordisk | May 4, 2018 | 303 |
| NCT02963935Nutrition Disorders · United States | 3 | Completed | Novo Nordisk | May 23, 2018 | 282 |
| NCT02963922Nutrition Disorders · United States, Canada, Germany and more | 3 | Completed | Novo Nordisk | Sep 10, 2018 | 396 |
| NCT02918279Nutrition Disorders · United States, Belgium, Mexico and more | 3 | Completed | Novo Nordisk | Feb 14, 2019 | 251 |
| NCT02911948Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Nov 17, 2017 | 210 |
| NCT02773368Diabetes Mellitus · United States, Argentina, Canada and more | 3 | Completed | Novo Nordisk | Sep 26, 2017 | 420 |
| NCT02730377Diabetes Mellitus · United States, Canada, Colombia and more | 4 | Completed | Novo Nordisk | Aug 5, 2019 | 1,991 |
| NCT02717858Nutrition Disorders · Denmark | 1 | Completed | Novo Nordisk | Feb 27, 2017 | 52 |
| NCT02696148Nutrition Disorders · United States | 1 | Completed | Novo Nordisk | Apr 13, 2017 | 24 |
| NCT02607306Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Dec 15, 2017 | 819 |
| NCT02527200Nutrition Disorders · United States, Australia, Canada and more | 3 | Completed | Novo Nordisk | Nov 4, 2020 | 56 |
| NCT02505334Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | May 2, 2017 | 635 |
| NCT02501161Diabetes Mellitus · United States, Argentina, Brazil and more | 3 | Completed | Novo Nordisk | Oct 3, 2018 | 1,012 |
| NCT02443155Diabetes Mellitus · United States, Austria, Belgium and more | 2 | Completed | Novo Nordisk | Aug 31, 2018 | 308 |
| NCT02420262Diabetes Mellitus · United States, Argentina, Czechia and more | 3 | Completed | Novo Nordisk | Oct 5, 2016 | 506 |
| NCT02298192Diabetes Mellitus · United States, Austria, Bulgaria and more | 3 | Completed | Novo Nordisk | Dec 23, 2015 | 420 |
| NCT02207348Nutrition Disorders · Germany | 1 | Completed | Novo Nordisk | Sep 2014 | 24 |
| NCT02100475Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Apr 2015 | 31 |
| NCT02098395Diabetes Mellitus · United States, Austria, Belgium and more | 3 | Completed | Novo Nordisk | Apr 2015 | 835 |
| NCT02072096Diabetes Mellitus, Type 2 · United States, Austria, Germany and more | 4 | Terminated | Eli Lilly | Oct 2015 | 192 |
| NCT02008682Diabetes Mellitus · China | 4 | Completed | Novo Nordisk | Nov 2014 | 368 |
| NCT01973231Diabetes Mellitus · Czech Republic, Finland, France and more | 4 | Completed | Novo Nordisk | Nov 2014 | 404 |
| NCT01952145Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Nov 4, 2014 | 557 |
| NCT01916174Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Nov 2013 | 50 |
| NCT01917656Diabetes Mellitus · Algeria, India, Israel and more | 4 | Completed | Novo Nordisk | Sep 1, 2014 | 343 |
| NCT01907854Diabetes Mellitus · United States, Canada, Hungary and more | 4 | Completed | Novo Nordisk | Jun 15, 2015 | 407 |
| NCT01870297Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Dec 2014 | 72 |
| NCT01836523Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Jun 2015 | 1,398 |
| NCT01789086Nutrition Disorders · Germany | 1 | Completed | Novo Nordisk | May 2014 | 21 |
| NCT01620489Diabetes Mellitus · United States, France, Poland and more | 3 | Completed | Novo Nordisk | Aug 20, 2013 | 279 |
| NCT01620476Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Mar 2004 | 24 |
| NCT01620463Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Mar 2003 | 32 |
| NCT01617434Diabetes Mellitus · United States, Argentina, Canada and more | 3 | Completed | Novo Nordisk | Oct 2013 | 451 |
| NCT01615978Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Mar 2004 | 15 |
| NCT01572740Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Nov 1, 2012 | 257 |
| NCT01557166Nutrition Disorders · United States, Canada | 3 | Completed | Novo Nordisk | Jun 1, 2013 | 359 |
| NCT01541215Diabetes Mellitus · United States, Australia, Austria and more | 3 | Completed | Novo Nordisk | Nov 15, 2017 | 135 |
| NCT01536665Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Aug 2012 | 45 |
| NCT01517568Diabetes Mellitus · Netherlands | 1 | Completed | Novo Nordisk | Dec 2006 | 7 |
| NCT01517555Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | May 2007 | 18 |
| NCT01516255Diabetes Mellitus · United States | 1 | Completed | Novo Nordisk | Nov 2006 | 64 |
| NCT01515592Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Apr 2006 | 24 |
| NCT01515579Diabetes Mellitus · Sweden | 1 | Completed | Novo Nordisk | Jun 2006 | 22 |
| NCT01515553Diabetes Mellitus · Sweden | 1 | Completed | Novo Nordisk | Apr 2007 | 22 |
| NCT01518166Diabetes Mellitus · Sweden | 1 | Completed | Novo Nordisk | Apr 2007 | 70 |
| NCT01514487Diabetes Mellitus · Australia | 1 | Completed | Novo Nordisk | Mar 30, 2005 | 24 |
| NCT01513525Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | May 2007 | 21 |
How it is read
Names in the registry
- “liraglutide”, 114 entries
- “insulin degludec/liraglutide”, 11 entries
- “Liraglutide”, 10 entries
- “Insulin degludec/liraglutide”, 3 entries
- “NN9924 (oral)”, 2 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 75 studies
- Obesity, 18 studies
- Diabetes Mellitus, 14 studies
- Diabetes Mellitus, Type 1, 5 studies
- Osteoarthritis, Knee, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.